Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 765,484 shares, an increase of 231.8% from the May 31st total of 230,679 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 346,077 shares, the short-interest ratio is presently 2.2 days.
Institutional Trading of Cel-Sci
Several hedge funds and other institutional investors have recently bought and sold shares of CVM. Renaissance Technologies LLC boosted its stake in Cel-Sci by 133.0% during the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock worth $115,000 after buying an additional 20,484 shares during the period. XTX Topco Ltd purchased a new position in shares of Cel-Sci during the 4th quarter worth about $66,000. State Street Corp grew its holdings in Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after purchasing an additional 2,300 shares during the last quarter. Jane Street Group LLC purchased a new stake in Cel-Sci in the 4th quarter worth about $83,000. Finally, HRT Financial LP bought a new stake in Cel-Sci in the fourth quarter worth about $60,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.
Cel-Sci Price Performance
NYSEAMERICAN:CVM traded up $0.14 during trading hours on Friday, reaching $1.11. The stock had a trading volume of 327,202 shares, compared to its average volume of 366,994. The stock has a market capitalization of $19.40 million, a PE ratio of -0.11 and a beta of 0.54. Cel-Sci has a 52 week low of $0.89 and a 52 week high of $13.48. The company has a 50 day moving average price of $1.82 and a two-hundred day moving average price of $3.73. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.54 and a current ratio of 0.60.
About Cel-Sci
CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.
The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.
Featured Articles
- Five stocks we like better than Cel-Sci
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.
